210 related articles for article (PubMed ID: 15932532)
1. Relationship between histopathological features of chemotherapy treated retinoblastoma and P-glycoprotein expression.
Souza Filho JP; Martins MC; Caissie AL; Torres VL; Fernandes LH; Erwenne CM; Burnier MN
Clin Exp Ophthalmol; 2005 Jun; 33(3):279-84. PubMed ID: 15932532
[TBL] [Abstract][Full Text] [Related]
2. Histopathological features and P-glycoprotein expression in retinoblastoma.
Filho JP; Correa ZM; Odashiro AN; Coutinho AB; Martins MC; Erwenne CM; Burnier MN
Invest Ophthalmol Vis Sci; 2005 Oct; 46(10):3478-83. PubMed ID: 16186322
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological parameters and expression of P-glycoprotein and MRP-1 in retinoblastoma.
Kamburoğlu G; Kiratli H; Söylemezoğlu F; Bilgiç S
Ophthalmic Res; 2007; 39(4):191-7. PubMed ID: 17596751
[TBL] [Abstract][Full Text] [Related]
4. Histopathologic findings in eyes with retinoblastoma treated only with chemoreduction.
Demirci H; Eagle RC; Shields CL; Shields JA
Arch Ophthalmol; 2003 Aug; 121(8):1125-31. PubMed ID: 12912690
[TBL] [Abstract][Full Text] [Related]
5. Multidrug resistant proteins: P-glycoprotein and lung resistance protein expression in retinoblastoma.
Krishnakumar S; Mallikarjuna K; Desai N; Muthialu A; Venkatesan N; Sundaram A; Khetan V; Shanmugam MP
Br J Ophthalmol; 2004 Dec; 88(12):1521-6. PubMed ID: 15548804
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant/adjuvant treatment of high-risk retinoblastoma: a report from the German Retinoblastoma Referral Centre.
Künkele A; Wilm J; Holdt M; Lohmann D; Bornfeld N; Eggert A; Temming P; Schulte JH
Br J Ophthalmol; 2015 Jul; 99(7):949-53. PubMed ID: 25583279
[TBL] [Abstract][Full Text] [Related]
7. Combined chemotherapy and local treatment in the management of intraocular retinoblastoma.
Brichard B; De Bruycker JJ; De Potter P; Neven B; Vermylen C; Cornu G
Med Pediatr Oncol; 2002 Jun; 38(6):411-5. PubMed ID: 11984802
[TBL] [Abstract][Full Text] [Related]
8. Postenucleation adjuvant chemotherapy with vincristine, etoposide, and carboplatin for the treatment of high-risk retinoblastoma.
Kaliki S; Shields CL; Shah SU; Eagle RC; Shields JA; Leahey A
Arch Ophthalmol; 2011 Nov; 129(11):1422-7. PubMed ID: 22084213
[TBL] [Abstract][Full Text] [Related]
9. Management and outcome of retinoblastoma with vitreous seeds.
Manjandavida FP; Honavar SG; Reddy VA; Khanna R
Ophthalmology; 2014 Feb; 121(2):517-24. PubMed ID: 24572675
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of a two-drug chemotherapy regimen for intraocular retinoblastoma.
Zage PE; Reitman AJ; Seshadri R; Weinstein JL; Mets MB; Zeid JL; Greenwald MJ; Strauss LC; Goldman S
Pediatr Blood Cancer; 2008 Mar; 50(3):567-72. PubMed ID: 17729249
[TBL] [Abstract][Full Text] [Related]
11. De novo intraocular retinoblastoma development after chemotherapy in patients with hereditary retinoblastoma.
Schueler AO; Anastassiou G; Jurklies C; Havers W; Wieland R; Bornfeld N
Retina; 2006 Apr; 26(4):425-31. PubMed ID: 16603962
[TBL] [Abstract][Full Text] [Related]
12. Expression of heat shock protein 27 and alpha-crystallins in human retinoblastoma after chemoreduction.
Kase S; Parikh JG; Rao NA
Br J Ophthalmol; 2009 Apr; 93(4):541-4. PubMed ID: 18812387
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant chemotherapy for extensive unilateral retinoblastoma.
Bellaton E; Bertozzi AI; Behar C; Chastagner P; Brisse H; Sainte-Rose C; Doz F; Desjardins L
Br J Ophthalmol; 2003 Mar; 87(3):327-9. PubMed ID: 12598448
[TBL] [Abstract][Full Text] [Related]
14. Expression of C-kit in retinoblastoma: a potential therapeutic target.
Barry RJ; de Moura LR; Marshall JC; Fernandes BF; Orellana ME; Antecka E; Martins C; Burnier MN
Br J Ophthalmol; 2007 Nov; 91(11):1532-6. PubMed ID: 17591671
[TBL] [Abstract][Full Text] [Related]
15. Development of new retinoblastomas after 6 cycles of chemoreduction for retinoblastoma in 162 eyes of 106 consecutive patients.
Shields CL; Shelil A; Cater J; Meadows AT; Shields JA
Arch Ophthalmol; 2003 Nov; 121(11):1571-6. PubMed ID: 14609913
[TBL] [Abstract][Full Text] [Related]
16. Chemoreduction improves eye retention in patients with retinoblastoma: a report from the German Retinoblastoma Reference Centre.
Künkele A; Jurklies C; Wieland R; Lohmann D; Bornfeld N; Eggert A; Schulte JH
Br J Ophthalmol; 2013 Oct; 97(10):1277-83. PubMed ID: 23863458
[TBL] [Abstract][Full Text] [Related]
17. What is the best treatment for retinoblastoma?
Harbour JW
Am J Ophthalmol; 2004 Sep; 138(3):471-3. PubMed ID: 15364232
[No Abstract] [Full Text] [Related]
18. A 10-year experience of outcome in chemotherapy-treated hereditary retinoblastoma.
Bartuma K; Pal N; Kosek S; Holm S; All-Ericsson C
Acta Ophthalmol; 2014 Aug; 92(5):404-11. PubMed ID: 24119165
[TBL] [Abstract][Full Text] [Related]
19. Causes of chemoreduction failure in retinoblastoma and analysis of associated factors leading to eventual treatment with external beam radiotherapy and enucleation.
Gündüz K; Günalp I; Yalçindağ N; Unal E; Taçyildiz N; Erden E; Geyik PO
Ophthalmology; 2004 Oct; 111(10):1917-24. PubMed ID: 15465557
[TBL] [Abstract][Full Text] [Related]
20. [Results of combined chemotherapy and local ophtalmic therapy of children with intraocular retinoblastoma].
Balwierz W; Kobylarz J; Starzycka M; Dluzniewska A
Med Wieku Rozwoj; 2001; 5(3 Suppl 1):15-23. PubMed ID: 12004148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
